ReCor Medical Expands Its Medical Advisory Board
MENLO PARK, Calif.--(BUSINESS WIRE)--Click here for video interviews
ReCor Medical announced today that it has expanded its medical advisory board in anticipation of conducting post-market clinical studies of its next-generation PARADISE® System for treatment of resistant hypertension via renal denervation—the only system for renal denervation that is based on ultrasound, not radiofrequency, energy. The new medical advisors are: Peter J. Fitzgerald, M.D., Ph.D., Stanford University School of Medicine, Stanford, Calif.; Thomas Mabin, M.D., Vergelegen Medi-Clinic, South Africa; Krishna J. Rocha-Singh, M.D., Praririe Cardiovascular, Springfield, Ill; and Karl-Heinz Kuck, M.D., Ph.D., Asklepios Klinik, Hamburg, Germany.
ReCor Medical announced today that it has expanded its medical advisory board in anticipation of conducting post-market clinical studies of its next-generation PARADISE® System for treatment of resistant hypertension via renal denervation—the only system for renal denervation that is based on ultrasound, not radiofrequency, energy. The new medical advisors are: Peter J. Fitzgerald, M.D., Ph.D., Stanford University School of Medicine, Stanford, Calif.; Thomas Mabin, M.D., Vergelegen Medi-Clinic, South Africa; Krishna J. Rocha-Singh, M.D., Praririe Cardiovascular, Springfield, Ill; and Karl-Heinz Kuck, M.D., Ph.D., Asklepios Klinik, Hamburg, Germany.